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ABSTRACT 
 
In the present investigation, a direct, simple and sensitive visible spectrophotometric method without using any 
buffer solution is described for the assay of tenofovir disproxil fumarate in pure and tablet dosage forms. The 
method is based on the formation of yellowish brown colored species by the drug with NQS reagent and exhibits 
absorption maxima at 451 nm. Regression analysis of Beer-Lambert plots showed good correlation in the 
concentration ranges (8-40) µg/ml. The proposed method is applied to commercial available tablets and the results 
are statistically compared with those obtained by the reported UV reference method and validated by recovery 
studies. The results are found satisfactory and reproducible. The method is applied successfully for the estimation of 
the tenofovir disproxil fumarate in the presence of other ingredients that are usually present in dosage forms. The 
method offers the advantages of rapidity, simplicity and sensitivity and normal cost and can be easily applied to 
resource-poor settings without the need for expensive instrumentation and reagents.     
Key words:  Assay, Beer’s Law, Chemotherauptic agent, NQS reagent, Regression equation, Statistical analysis. 
INTRODUCTION: 
 Tenofovir Disoproxil Fumarate (TDF) (Fig.1) is an antiretroviral agent belonging to the class of nucleotide 
reverse transcriptase inhibitors (NRTI) used in the management of HIV infection in adults. It is an orally bio 
available pro drug of tenofovir and the first nucleotide analogue approved for HIV-1 treatment1-2. In vivo, TDF is 
converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5’-monophosphate. 
Tenofovir exhibits activity against HIV-1, HIV-2 and hepatitis-B virus. Chemically it is the 1:1 salt of the bis-
isopropyloxy carbonyl oxy methyl ester of tenofovir and fumaric acid [9-[(R)-2-[[bis [(isopropoxycarbonyl) oxy] 
methyl] phosphinyl] methoxy] propyl] adenine fumarate]. Its empirical formula is C19H30N5O10P.C4H4O4   
representing   molecular weight of 635.52. It is a white to off-white crystalline powder with a solubility of 
13.4mg/ml in distilled water and freely soluble in methanol and in DMF. The drug is available in tablet dosage 
forms only. TDF remains in cells for longer periods of time than many other antiretroviral drugs, thereby allowing 
for once-daily dosing. The drug is official in IP3. 
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 Figure 1: Chemical structure of tenofovir disproxil fumarate 
 Before phosphorylation, TDF is converted to tenofovir in the intestinal lumen and plasma by diester hydrolysis. 
Tenfovir then internalized into cells, possibly by endocytosis, and subsequently phosphorylated in sequential steps 
to tenfovir monophosphate and to the active metabolite, tenfovir diphosphate. In a mechanism similar to that of 
NRTI’s, tenfovir diphosphate competes with its natural nucleotide counterpart deoxyadenosine5’-triphosphate, for 
incorporation into newly forming HIV DNA. Once successfully incorporated, termination of the elongating DNA 
chain ensues, and DNA synthesis is interrupted.  
Extensive literature review reveals that several spctrophotometric UV4-11 &Visible12-15, HPLC16-24, HPTLC25-26 and 
LC/LC-MS27-33 methods have been reported so far for determination of tenofovir alone and its combination with 
other drugs. Even though some visible spectrophotometric assay procedures have been reported for the 
determination of TDF, many of them concern with biological fluid samples and very few in pharmaceutical 
formulations and functional groups present in the drug not fully exploited. So the author has made some attempts in 
this direction and succeeded in developing the method based on the reaction between the drug and folin reagent 
(NQS) 34 in presence of NaOH instead of phosphate buffer pH8.0 under specified experimental conditions. The 
method can be extended for the routine quality control analysis of pharmaceutical products containing TDF. 
MATERIALS & METHODS (EXPERIMENTAL) 
 Apparatus and chemicals: A Shimadzu UV-Visible spectrophotometer 1800 with10mm matched quartz cells was 
used for all spectral measurements. A Systronics digital pH meter mode-361 was used for pH measurements. All the 
chemicals used were of analytical grade.  
Folin reagent (NQS) solution (Loba, 0.5%, 1.93x10-2M prepared by dissolving 500mg of NQS in 100 ml of distilled 
water), NaOH solution (E. Merck, 20%, 5M prepared by dissolving 20 g of NaOH in 100 ml of distilled water) were 
prepared.  
Preparation of Bulk and Sample solution: About 100mg of TDF [pure or formulation] was accurately weighed 
and dissolved in  100ml of 3M Hydrochloric acid in a volumetric flask to form the stock solution of 1mg/ml. The 
solution was refluxed gently for 60 minutes to hydrolyze the phosphate groups from the drug. The hydrolyzed drug 
was partitioned with chloroform (25ml x4). The chloroform extract was evaporated to dryness and the residue so 
obtained was dissolved in 10 ml 0.1M sodium hydroxide and the volume was brought to 100 ml with distilled water. 
The working standard solution of TDF (200 µg/ml) was obtained by appropriately diluting the standard stock 
solution with the same solvent. The prepared stock solution was stored at 4϶ C protected from light. From this stock 
solution, a series of standards were freshly prepared during the analysis day. 
Determination of wavelength maximum (Ȝ max):  
The 5.0  ml  of working standard solution of TDF (200µg/ml) was taken in 25ml standard flask. To this, 0.5ml of 
folin reagent (1.092x10-2M), 1.0ml NaOH and 1.5ml of distilled water were added and kept aside for 15 min for 
complete color development. Then the volume was made up to 25 ml using distilled water and sonicated for 1 
minute to get a concentration of 40µg/ml. In order to investigate the wavelength maximum, the above standard stock 
solution was scanned in the range of 360-560nm by UV-Visible spectrophotometer. From the spectra (Fig.2), it was 
concluded that 451nm is the most appropriate wavelength for analyzing TDF with suitable sensitivity.  
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Figure 2: Absorption spectra of TDF-NQS system 
Preparation of calibration curve:   
Aliquots of the standard TDF solution [1.0-5.0ml, 200µg/ml] were placed in a series of 25ml standard flask. Then 
0.5ml of folin reagent (1.092x10-2M), 1.0ml NaOH and 1.5ml of distilled water were added and kept aside for 15 
min for complete color development. Then the volume was made up to 25 ml using distilled water and sonicated for 
1 minute. The absorbance was measured at 451 nm against a reagent blank within the stability period (5minutes to 
30min). The calibration graph was constructed by plotting the drug concentration versus absorbance. The amount of 
drug was computed from its calibration graph (Fig.3).  
 
 Figure 3: Calibration graph of TDF-NQS system 
RESULTS AND DISCUSSION 
Optimum operating conditions used in the procedure were established by adopting variation of one variable at a time 
(OVAT) method.  The effect of various parameters such as time, volume and strength of reagents, the order of 
addition of reagents and solvent for final dilution of the colored species were studied. Distilled water was found to 
be best solvent for final dilution. Other water miscible solvents like methanol, ethanol, propan-2-ol and acetonitrile 
have no additional advantage in increasing the intensity of the color.  The optical characteristics such as Beer’s law 
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limit, Sandell‘s sensitivity, molar absorptivity, percent relative standard deviation, (calculated from the six 
measurements containing 3/4th of the amount of the upper Beer’s law limits), Regression characteristics like 
standard deviation of slope (Sb), standard deviation of intercept (Sa), standard error of estimation (Se) and % range of 
error (0.05 and 0.01 confidence limits) were calculated and the results are summarized in Table-1.  
Commercial formulations containing TDF were successfully analyzed by the proposed method. The values obtained 
by the proposed and reference method (reported UV method using distilled water after dissolving in 1ml methanol, ˏ 
max=260nm)  for formulations were compared statistically by the t-and F-test and found not to differ significantly. As 
an additional demonstration of accuracy, recovery experiments were performed by adding a fixed amount of the 
drug to the pre analyzed formulations at three different concentration levels. These results are summarized in Table-
2.  
Chemistry of colored species: 
In the present investigation, the presence of hetrocyclic amino moiety of TDF permits the development of visible 
spectrophotometric method for its determination. Yellowish brown colored species (N-alkyl amino napthaquinone) 
was formed by replacement of the sulphonate group of the napthaquinone sulphonic acid by a primary amino group 
of drug. The formation of colored species with the reagent may be assigned through above analogy as shown in 
scheme (Fig.4).  
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Fig.4: Probable scheme of the reaction 
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TABLE 1: OPTICAL CHARACTERISTICS, PRECISION AND ACCURACY OF PROPOSED METHOD. 
Parameter Values 
 
ʢmax  (nm) 451 
Beer’s law limit(µg/ml) 8-40 
Sandell’s sensitivity  (µg/cm2/0.001 abs. unit 0.002990654 
Molar absorptivity (Litre/mole/cm) 212502 
Regression equation         (Y)*  
Intercept (a) 0.018 
Slope(b) 0.013 
 %RSD 1.58 
% Range of errors(95% Confidence  limits) 
 
 
0.05 significance level 
 
1.66 
0.01 significance level 
 2.59 
 
*Y = a+ b x, where Y is the absorbance and x is the concentration of TDF in µg/ml 
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TABLE 2: ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE BY PROPOSED AND REFERENCE 
METHODS. 
 
Method *Formulations Labeled 
Amount 
(mg) 
Found by Proposed Method Found by 
Reference 
Method  ± 
SD 
#% Recovery 
by Proposed 
Method ± SD 
**Amount 
found ± SD 
t F 
NQS   Batch-1 
 
300 298.18 ± 
0.68 
1.97 3.2 297.49±0.38 99.39 ±  0.23 
Batch-2 300 297.11  ± 
2.01 
0.14 1.28 296.85±1.78 99.04 ±  0.67 
 
* Batch 1 and Batch 2 are different pharmaceutical companies of Tenof (Hetro) and Tavin (Emcure).   
 **Average ± Standard deviation of six determinations, the t- and F-values refer to comparison of the proposed 
method with reference method. (UV). Theoretical values at 95% confidence limits t =2.57 and F = 5.05. 
# Recovery of 10mg added to the pre analyzed sample (average of three determinations).  
Reference method (reported UV method) using distilled water after dissolving in 1ml methanol (ˏ max=260nm). 
CONCLUSION 
The reagents utilized in the proposed method are normal cost, readily available in all chemical laboratories and 
small scale industries and the procedure does not involve any critical reaction conditions or tedious sample 
preparation. The proposed colorimetric method possesses reasonable precision, accuracy, and simple, sensitive and 
can be used as alternative method to the reported ones for the routine determination of TDF depending on the need 
and situation.   
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